Contrasting of ANI Pharmaceuticals Inc. (ANIP) and Aytu BioScience Inc. (NASDAQ:AYTU)

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Aytu BioScience Inc. (NASDAQ:AYTU) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals Inc. 191.74M 3.50 N/A 1.18 46.66
Aytu BioScience Inc. 4.02M 2.59 9.39M -24.28 0.00

Demonstrates ANI Pharmaceuticals Inc. and Aytu BioScience Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 represents ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Aytu BioScience Inc. (NASDAQ:AYTU)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals Inc. 0.00% 0.2% 0.1%
Aytu BioScience Inc. -233.58% -95.5% -46.2%

Volatility and Risk

ANI Pharmaceuticals Inc.’s current beta is 2.45 and it happens to be 145.00% more volatile than Standard & Poor’s 500. Aytu BioScience Inc.’s 374.00% more volatile than Standard & Poor’s 500 volatility due to the company’s 4.74 beta.

Liquidity

ANI Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 3.3 and 2.5 respectively. The Current Ratio and Quick Ratio of its competitor Aytu BioScience Inc. are 1.9 and 1.6 respectively. ANI Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Aytu BioScience Inc.

Analyst Recommendations

ANI Pharmaceuticals Inc. and Aytu BioScience Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ANI Pharmaceuticals Inc. 0 0 1 3.00
Aytu BioScience Inc. 0 0 0 0.00

ANI Pharmaceuticals Inc.’s average price target is $70, while its potential upside is 23.46%.

Institutional and Insider Ownership

Roughly 84.7% of ANI Pharmaceuticals Inc. shares are owned by institutional investors while 2.9% of Aytu BioScience Inc. are owned by institutional investors. About 0.4% of ANI Pharmaceuticals Inc.’s share are owned by insiders. Insiders Comparatively, owned 18.6% of Aytu BioScience Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ANI Pharmaceuticals Inc. -1.21% -0.63% -0.62% -17.28% -18.38% -14.79%
Aytu BioScience Inc. -9.16% -17.34% -69.82% -85.57% -98.22% -97.94%

For the past year ANI Pharmaceuticals Inc. was less bearish than Aytu BioScience Inc.

Summary

On 11 of the 11 factors ANI Pharmaceuticals Inc. beats Aytu BioScience Inc.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. Further, the company provides Fiera personal care device, a hands-free wearable product for women that is designed to enhance interest in and physical readiness for sex. Aytu BioScience, Inc. is based in Englewood, Colorado.